Device Treatment of Recurrent Or Refractory Ascites Due To Liver Cirrhosis

Alfapump System

Payments companies reported to CMS as associated with Alfapump System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$8,505associated payments (2023-2025)
36clinicians with associated payments
1company reporting

By year

2025 $8,505

Payments reported as associated with Alfapump System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $5,774
Vascular & Interventional Radiology $804
Internal Medicine $757
Physician Assistant $644
Transplant Hepatology $231
Hospice and Palliative Medicine (Internal Medicine) $222

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Alfapump System

These are the largest totals companies reported as associated with Alfapump System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Kuchikala Reddy Philadelphia, PA Gastroenterology (Internal Medicine) $3,390.00
Hugo Vargas Scottsdale, AZ Gastroenterology (Internal Medicine) $259.77
Alexander Scherer Indianapolis, IN Internal Medicine $222.27
Archita Desai Indianapolis, IN Gastroenterology (Internal Medicine) $222.27
Amy Johnson Indianapolis, IN Hospice and Palliative Medicine (Internal Medicine) $222.27
Eric Orman Indianapolis, IN Gastroenterology (Internal Medicine) $222.27
Claudia Craig Indianapolis, IN Physician Assistant $222.27
Raj Vuppalanchi Indianapolis, IN Internal Medicine $222.27
Haleigh Rodgers Indianapolis, IN Physician Assistant $222.27
Michele Barnhill Scottsdale, AZ Gastroenterology (Internal Medicine) $219.93

Prescribed Alfapump System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.